Preclinical trial explores bivalent CAR targeting both CD19 and CD22, suggesting reduced antigen loss risk.
relapse following CD19-directed CAR therapy. The CD19/CD22 bivalent CAR provides an opportunity to test whether simultaneous targeting may reduce risk of antigen loss.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: